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E D I T O R I A L
Early COVID-19 testing is critical to end the pandemic
1  | THE ROLE OF TESTING IN MEDICINE 
AND PUBLIC HE ALTH
Testing is critical to break transmission chains of severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) and end the coro-
navirus disease 2019 (COVID-19) pandemic, but there are slight 
differences in its roles between medicine and public health. In 
medicine, protecting the health of the individual through preven-
tion, diagnosis, and treatment is prioritized. Public health mainly 
focuses on improving population health and tries to promptly de-
tect suspected outbreaks, prevent and control their spread, and 
enhance the surveillance system. The European Centre for Disease 
Prevention (ECDC) summarizes five objectives of testing: (a) to 
control transmission; (b) to monitor SARS-CoV-2 transmission rates 
and severity; (c) to mitigate the impact of COVID-19 in healthcare 
and social care settings; (d) to detect clusters or outbreaks in spe-
cific settings; and (e) to maintain COVID-19 elimination status once 
achieved.1
To meet the first objective, all individuals with suspected 
COVID-19 symptoms must be promptly identified and tested 
after the onset of their symptoms. This is recommended by many 
public health agencies or other organizations at the global scale 
and practiced accordingly (Table 1). In medical perspectives, early 
detection of COVID-19 can contribute to preventing sudden 
death as the pathogenesis of silent hypoxia has not been clari-
fied. Considering an extended duration for virus shedding under 
specific circumstances, including immunocompromised patients, 
testing will also help recognize their viral load and clinical course. 
Moreover, diagnosing patients as COVID-19 may eventually en-
sure that patients who suffer from long COVID can access to the 
social and medical support. Regarding advantages of testing in 
public health, detecting additional sporadic cases and clusters, 
in line with timely isolation, rigorous contact tracing, and quar-
antine, prevents further transmission. Besides, enhanced popu-
lation-based surveillance is vital to achieve the second objective 
and inform the public health decision. Healthcare workers (HCWs) 
in both primary healthcare and hospital settings are expected to 
be involved in this process.1
2  | A PUZZLING CONTROVERSY IN JAPAN: 
ACCESS TO TESTING AND PERFORMANCE 
OF RT-PCR TEST
While many countries gravely expanded the testing capacity for 
diagnosing COVID-19, citizens’ access to testing had not been ad-
equately ensured in Japan.2,3 Although the infectiousness among 
asymptomatic and presymptomatic individuals had been recognized 
in earlier phase, patients suffered from COVID-19–related symp-
toms were generally instructed to stay home for 4 days in early 
2020.2 Even after lifting the state of emergency in May, Japan made 
insufficient efforts to ramp up its testing capacity and logistics, and 
some professional societies still argue that self-isolation at home 
must be prioritized compared with early testing (Table 1).
In addition, there has been a puzzling discussion regarding the 
performance of reverse transcription-polymerase chain reaction 
(RT-PCR) test. The nucleic acid amplification tests (NAATs), includ-
ing RT-PCR test, are the gold standard for diagnosis, and 100% 
specificity has been a scientific consensus;4 however, its specific-
ity was perplexingly downgraded as low as 99% or 99.9% without 
presenting any solid evidence. False-positive COVID-19 results 
were criticized in a nonscientific manner,3 and scant discussion 
addressed the importance of external quality assessment schemes 
from the third party, which are necessary to prevent technical er-
rors and reagent or laboratory contamination.5 Scientific evidence, 
and COVID-19 data reported in Australia, New Zealand, China, 
and several other countries that achieved COVID-19 elimination 
or containment could evidently reject this factitious argument.3,6 
Regarding sensitivity, there are several reasons to bring negative 
results among infected individuals, and RT-PCR test has been clin-
ically used to rule-in COVID-19 cases.5 Nevertheless, negative re-
sults were excessively conceptualized as whether investing in public 
health infrastructure and bolstering COVID-19 tests will bring sev-
eral disadvantages. Lack of knowledge and critical thinking among 
some HCWs, absence of their independent drive to learn from the 
multidisciplinary science, insufficiency of scientific journalism, and 
weakness in health communication2 perplexingly brought the dis-
torted science to the public.
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3  | PHYSICIANS’  ACCOUNTABILIT Y 
DURING HE ALTH EMERGENCY
To combat against the COVID-19 pandemic, building a consolidated 
command and control system is vital. Presenting a clear grand strat-
egy based on excellent science will help front-line HCWs, including 
physicians, to correctly understand their roles in both medicine and 
public health, and successfully run find-test-trace-isolate-support 
systems.
First and foremost, physicians need to change their mind-
set and remove their biases. As the infectiousness of COVID-19 
starts before the onset of symptoms,7 all patients with suspected 
COVID-19 symptoms, even milder cases, must be promptly tested. 
This will protect patients’ health and break transmission chains. 
RT-PCR testing is the gold-standard diagnostic test; therefore, it 
must be noted that joining the pseudoscience is completely con-
tradictory to physicians’ professionalism. As every testing helps 
to end the pandemic, ensuring citizens’ access to testing is criti-
cal. Launching and managing test centers to the entire nation and 
strengthening logistics for postal testing service will ease citizens’ 
psychological barriers to testing and help detect more asymptom-
atic and presymptomatic COVID-19 patients with transmissibility. 
These opportunities will accelerate COVID-19 screening among es-
sential workers who work in high-risk environments. HCWs need 
to embrace people who have cooperated with COVID-19 testing, 
rather than just ask citizens to comply with additional personal hy-
giene practices.
Second, HCWs must continuously learn from excellent science, 
regularly update their knowledge, critically appraise literature, re-
view previous fallacies, and incorporate latest insights. The ongo-
ing COVID-19 pandemic explicitly suggested that policymakers and 
even some scientists sometimes ignored, cherry-picked, and dis-
torted science. Japan has been no exception.2 Without examining 
previous errors and getting appropriate feedback, the same mistakes 
will be repeated, thus magnifying patients’ risk.
The COVID-19 pandemic in Japan elucidated that some 
physicians were not conscious of their roles for improving and 
promoting public health, as specified in Article 1 of the Medical 
Practitioners' Act. Physicians must note that solely appreciating 
medical perspectives and downgrading public health viewpoints 
are contradictory to their professionalism. As guaranteeing cit-
izens’ access to testing and their social security during the iso-
lation/quarantine period will drastically change the landscape, 
and early containment of COVID-19 will contribute to protecting 
vulnerable populations and maintaining essential health services, 
physicians must be responsible for learning from previous errors, 
critically appraising the excellent science, and protecting patients 
from misinformation.
TA B L E  1   RT-PCR test indication among symptomatic patients with suspected COVID-19 in selected organizations
Organization Recommendation
Outside Japan
World Health Organization Anyone with symptoms should be tested, wherever possible.
Centers for Disease Control and Prevention, United 
States
People who have symptoms of COVID-19.
European Centre for Disease Prevention and Control Ideally, all people with COVID-19 symptoms should be tested as soon as possible 
after symptom onset.
Ministry of Health, Ontario, Canada Testing should be offered to, or arranged for, all patients with new or worsening 
symptoms that are compatible with COVID-19 where possible and appropriate.
Along with a different diagnosis (eg, bacterial infection), COVID-19 testing should 
be considered in parallel if warranted.
British Columbia Centre for Disease Control, Canada Recommend testing if any ONE of the following symptoms more predictive or 
strongly associated with COVID-19 is reported: fever or chills; new onset or 
worsening of chronic cough; loss of sense of smell or taste; difficulty breathing.
Japan
Japan Medical Association COVID-19 would be suspected after excluding infections by common respiratory 
pathogens such as bacteria, aspiration-related organisms, Mycoplasma, 
Chlamydophila.
Japan Primary Care Association Tests are considered for the following symptomatic patients: close contact history; 
high-risk patients; moderate to severe symptoms; mild symptoms for at least 
4 days.
Abbreviations: COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription-polymerase chain reaction.
The reference numbers of these organizations are shown in parentheses: World Health Organization.8 Centers for Disease Control and Prevention.9 
European Centre for Disease Prevention and Control.10 Ministry of Health, Ontario, Canada.11 British Columbia Centre for Disease Control, British 
Columbia, Canada.12 Japan Medical Association.13 Japan Primary Care Association.14
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